Results 21 to 30 of about 522 (82)
KRAS mutations dynamically remodel the tumor microenvironment (TME), fostering immunosuppression, metabolic symbiosis, and stromal plasticity. This review dissects how oncogenic KRAS variants sculpt TME networks and explores actionable vulnerabilities. Emerging strategies combining KRAS inhibitors and TME‐editing approaches offer potential to dismantle
Jiayao Ma +9 more
wiley +1 more source
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley +2 more sources
KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials. [PDF]
Navarro-Jiménez M +4 more
europepmc +1 more source
G protein selectivity in group I metabotropic glutamate receptors. [PDF]
Lu Y +8 more
europepmc +1 more source
Delineation of the GPR15 receptor-mediated Gα protein signalling profile in recombinant mammalian cells. [PDF]
Deng Y +6 more
europepmc +1 more source
G12/13 signaling in asthma. [PDF]
McDuffie EL, Panettieri RA, Scott CP.
europepmc +1 more source
GPCRome-wide analysis of G-protein-coupling diversity using a computational biology approach. [PDF]
Matic M +4 more
europepmc +1 more source
Structural insights into the G-protein subtype selectivity revealed by human sphingosine-1-phosphate receptor 3-G<sub>q</sub> complexes. [PDF]
Yamauchi M +12 more
europepmc +1 more source
G protein selectivity profile of GPR56/ADGRG1 and its effect on downstream effectors. [PDF]
Jallouli R +10 more
europepmc +1 more source

